Status:
COMPLETED
Carbetocin in the Prevention of Primary Postpartum Haemorrhage
Lead Sponsor:
Ministry of Health and Population, Egypt
Conditions:
Post Partum Hemorrhage
Eligibility:
FEMALE
20-40 years
Brief Summary
Postpartum haemorrhage (PPH) ranks as the first cause of maternal mortality in developing countries and it is the cause of 25% of maternal deaths worldwide. Carbetocin is a long-acting synthetic octa...
Detailed Description
Postpartum hemorrhage is defined as a blood loss more than 500 ml, and serious PPH as a blood loss more than 1,000 ml. It is a common maternal morbidity in high-resource countries and is trending upw...
Eligibility Criteria
Inclusion
- Age: 20-40years.
- Body mass index (BMI): Obese ≥30 kg/m2 and non-obese women \<30 kg/m2 calculated using maternal height and weight measured to the nearest centimeter and kilogram, respectively, at time of admission to labor word.
- Gestational age: Gestational age ≥37 weeks (gestational age will be recorded according to the last menstrual period and confirmed by ultrasound). In case of discrepancy, a 1st trimesteric ultrasound will be taken as the actual gestational age.
- Singleton pregnancy.
Exclusion
- Patients who have any factors that might increase the risk of postpartum haemorrhage will be excluded as anemic patients (Hb\<10.5g%), antepartum haemorrhage ( placenta previa, placental abruption ), uterine myomata, multiple gestation, polyhydramnios.
- Patients with pre-existing bleeding or thromboembolic disorder.
- Patients with chronic medical diseases (cardiac, hepatic, renal)
Key Trial Info
Start Date :
January 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 30 2023
Estimated Enrollment :
244 Patients enrolled
Trial Details
Trial ID
NCT06159959
Start Date
January 1 2023
End Date
October 30 2023
Last Update
December 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kasr- Alainy Hospitals
Cairo, Egypt